"IND clearance to proceed with BEACH301 is a significant milestone for the achondroplasia community and for TYRA, as we move into the clinic to treat our first rare skeletal dysplasia indication," ...

Overexpression of fibroblast growth factor receptor 3 (FGFR3) has been shown to drive oncogenesis in a subset of patients with multiple myeloma. However, epithelial cancers — such as bladder ...

ABOUT Achondroplasia Achondroplasia is disease in which a genetic mutation of the fibroblast growth factor receptor type 3 (FGFR3) causes FGFR3 to be activated, resulting in an excessive influx of ...

Achondroplasia is a rare genetic disorder of bone growth that causes short-limbed dwarfism. It occurs due to mutations in a single gene called the FGFR3.

The medicine is a daily injection, called vosoritide, which blocks a signal controlled by the faulty gene FGFR3 that impairs normal bone growth in children with achondroplasia. Researchers say the ...

Achondroplasia is a genetic skeletal condition ... and is caused by changes in the FGFR3 gene. In the study, grade 3 adverse events occurred in five kids and included hydrocephalus, adenoidal ...

"IND clearance to proceed with BEACH301 is a significant milestone for the achondroplasia community and for TYRA, as we move into the clinic to treat our first rare skeletal dysplasia indication," ...

BridgeBio (BBIO) announced that 18-month results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with ...

In September 2024, a manuscript titled "Discovery of TYRA-300: First oral selective FGFR3 inhibitor for the treatment of urothelial cancers and achondroplasia" was published in the Journal of ...